Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression

Genome Research

Volumn 22, Issue 7, 2012, Pages 1197-1211

  Selamat, Suhaida A ^a   Chung, Brian S ^a   Girard, Luc ^b   Zhang, Wei ^b   Zhang, Ying ^a   Campan, Mihaela ^a   Siegmund, Kimberly D ^a   Koss, Michael N ^a   Hagen, Jeffrey A ^a   Lam, Wan L ^c   Lam, Stephen ^c   Gazdar, Adi F ^b   Laird Offringa, Ite A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; LGALS4 PROTEIN; MESSENGER RNA; PROTEIN; PROTEIN KINASE LKB1; RAS PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN;

AGED; ARTICLE; CANCER TISSUE; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CIGARETTE SMOKING; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE MUTATION; GENOME ANALYSIS; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; DNA METHYLATION; EPIGENESIS, GENETIC; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GALECTIN 4; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; GENOME, HUMAN; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RNA, MESSENGER; SMOKING; WNT SIGNALING PATHWAY;

EID: 84863550037     PISSN: 10889051     EISSN: 15495469     Source Type: Journal    
DOI: 10.1101/gr.132662.111     Document Type: Article

References (158)

1. Acosta D, Suzuki M, Connolly D, Thompson RF, Fazzari MJ, Greally JM, Montagna C. 2011. DNA methylation changes in murine breast adenocarcinomas allow the identification of candidate genes for human breast carcinogenesis. Mamm Genome 22: 249-259.
2. Agarwal R, Mori Y, Cheng Y, Jin Z, Olaru AV, Hamilton JP, David S, Selaru FM, Yang J, Abraham JM, et al. 2009. Silencing of claudin-11 is associated with increased invasiveness of gastric cancer cells. PLoS ONE 4: e8002. doi: 10.1371/journal.pone.0008002.
3. Ahrendt SA, Decker PA, Alawi EA, Zhu YR, Sanchez-Cespedes M, Yang SC, Haasler GB, Kajdacsy-Balla A, Demeure MJ, Sidransky D. 2001. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 92: 1525-1530.
4. Andersson A, Srivastava MK, Harris-White M, Huang M, Zhu L, Elashoff D, Strieter RM, Dubinett SM, Sharma S. 2011. Role of CXCR3 ligands in IL-7/IL-7Rα-Fc-mediated antitumor activity in lung cancer. Clin Cancer Res 17: 3660-3672.
5. Barbosa-Morais NL, Dunning MJ, Samarajiwa SA, Darot JF, Ritchie ME, Lynch AG, Tavare S. 2010. A re-annotation pipeline for Illumina BeadArrays: Improving the interpretation of gene expression data. Nucleic Acids Res 38: e17. doi: 10.1093/nar/gkp942.
6. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, et al. 2002. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8: 816-824.
7. Belinsky SA. 2004. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 4: 707-717.
8. Belinsky SA, Palmisano WA, Gilliland FD, Crooks LA, Divine KK, Winters SA, Grimes MJ, Harms HJ, Tellez CS, Smith TM, et al. 2002. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 62: 2370-2377.
9. Bendik I, Schraml P, Lludwig CU. 1998. Characterization of MAST9/Hevin, a SPARC-like protein, that is down-regulated in non-small cell lung cancer. Cancer Res 58: 626-629.
10. Berman BP, Weisenberger DJ, Aman JF, Hinoue T, Ramjan Z, Liu Y, Noushmehr H, Lange CP, van Dijk CM, Tollenaar RA, et al. 2012. Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. Nat Genet 44: 40-46.
11. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, et al. 2001. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci 98: 13790-13795.
12. Boldin MP, Goncharov TM, Goltsev YV, Wallach D. 1996. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 85: 803-815.
13. Breitling LP, Yang R, Korn B, Burwinkel B, Brenner H. 2011. Tobacco-smoking-related differential DNA methylation: 27K discovery and replication. Am J Hum Genet 88: 450-457.
14. Brenet F, Moh M, Funk P, Feierstein E, Viale AJ, Socci ND, Scandura JM. 2011. DNA methylation of the first exon is tightly linked to transcriptional silencing. PLoS ONE 6: e14524. doi: 10.1371/journal.pone.0014524.
15. Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, Glockner S, Piantadosi S, Gabrielson E, Pridham G, et al. 2008. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 358: 1118-1128.
16. Campan M, Weisenberger DJ, Trinh B, Laird PW. 2009. MethyLight. Methods Mol Biol 507: 325-337.
17. Cancer Genome Atlas Research Network. 2011. Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615.
18. Cheong N, Zhang H, Madesh M, Zhao M, Yu K, Dodia C, Fisher AB, Savani RC, Shuman H. 2007. ABCA3 is critical for lamellar body biogenesis in vivo. J Biol Chem 282: 23811-23817.
19. + channel β1 subunit. Int J Biochem Cell Biol 41: 1216-1227.
20. Christensen BC, Marsit CJ, Houseman EA, Godleski JJ, Longacker JL, Zheng S, Yeh RF, Wrensch MR, Wiemels JL, Karagas MR, et al. 2009. Differentiation of lung adenocarcinoma, pleural mesothelioma, and nonmalignant pulmonary tissues using DNA methylation profiles. Cancer Res 69: 6315-6321.
21. Clark SJ. 2007. Action at a distance: Epigenetic silencing of large chromosomal regions in carcinogenesis. Hum Mol Genet 16: R88-R95.
22. Clausen KA, Blish KR, Birse CE, Triplette MA, Kute TE, Russell GB, D'Agostino RB Jr, Miller LD, Torti FM, Torti SV. 2011. SOSTDC1 differentially modulates Smad and b-catenin activation and is downregulated in breast cancer. Breast Cancer Res Treat 129: 737-746.
23. Dietrich D, Krispin M, Dietrich J, Fassbender A, Lewin J, Harbeck N, Schmitt M, Eppenberger-Castori S, Vuaroqueaux V, Spyratos F, et al. 2010. CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients. BMC Cancer 10: 247.
24. Divine KK, Pulling LC, Marron-Terada PG, Liechty KC, Kang T, Schwartz AG, Bocklage TJ, Coons TA, Gilliland FD, Belinsky SA. 2005. Multiplicity of abnormal promoter methylation in lung adenocarcinomas from smokers and never smokers. Int J Cancer 114: 400-405.
25. Dranoff G. 2004. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4: 11-22.
26. Du P, Kibbe WA, Lin SM. 2008. lumi: A pipeline for processing Illumina microarray. Bioinformatics 24: 1547-1548.
27. Esteller M. 2003. Relevance of DNA methylation in the management of cancer. Lancet Oncol 4: 351-358.
28. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. 1999. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 59: 67-70.
29. Fu DY, Wang ZM, Li C, Wang BL, Shen ZZ, Huang W, Shao ZM. 2010. Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer. Breast Cancer Res Treat 119: 601-612.
30. Galm O, Yoshikawa H, Esteller M, Osieka R, Herman JG. 2003. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 101: 2784-2788.
31. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, et al. 2004. Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol 5: R80.
32. Ghadersohi A, Odunsi K, Lele S, Collins Y, Greco WR, Winston J, Liang P, Sood AK. 2004. Prostate derived Ets transcription factor shows better tumor-association than other cancer-associated molecules. Oncol Rep 11: 453-458.
33. Goldenring JR, Nam KT. 2011. Rab25 as a tumour suppressor in colon carcinogenesis. Br J Cancer 104: 33-36.
34. Goto Y, Shinjo K, Kondo Y, Shen L, Toyota M, Suzuki H, Gao W, An B, Fujii M, Murakami H, et al. 2009. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. Cancer Res 69: 9073-9082.
35. Han H, Cortez CC, Yang X, Nichols PW, Jones PA, Liang G. 2011. DNA methylation directly silences genes with non-CpG island promoters and establishes a nucleosome occupied promoter. Hum Mol Genet 20: 4299-4310.
36. Hinoue T, Weisenberger DJ, Lange CP, Shen H, Byun HM, Van Den Berg D, Malik S, Pan F, Noushmehr H, van Dijk CM, et al. 2012. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res 22: 271-282.
37. Hiraoka N, Yamazaki-Itoh R, Ino Y, Mizuguchi Y, Yamada T, Hirohashi S, Kanai Y. 2011. CXCL17 and ICAM2 are associated with a potential antitumor immune response in early intraepithelial stages of human pancreatic carcinogenesis. Gastroenterology 140: 310-321.
38. Hou J, Aerts J, den Hamer B, van Ijcken W, den Bakker M, Riegman P, van der Leest C, van der Spek P, Foekens JA, Hoogsteden HC, et al. 2010. Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS ONE 5: e10312. doi: 10.1371/journal.pone.0010312.
39. Huang da W, Sherman BT, Lempicki RA. 2009. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
40. Huang J, Zheng DL, Qin FS, Cheng N, Chen H, Wan BB, Wang YP, Xiao HS, Han ZG. 2010. Genetic and epigenetic silencing of SCARA5 may contribute to human hepatocellular carcinoma by activating FAK signaling. J Clin Invest 120: 223-241.
41. Hu-Lowe DD, Chen E, Zhang L, Watson KD, Mancuso P, Lappin P, Wickman G, Chen JH, Wang J, Jiang X, et al. 2011. Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies. Cancer Res 71: 1362-1373.
42. Hussain M, Rao M, Humphries AE, Hong JA, Liu F, Yang M, Caragacianu D, Schrump DS. 2009. Tobacco smoke induces Polycomb-mediated repression of Dickkopf-1 in lung cancer cells. Cancer Res 69: 3570-3578.
43. Ibragimova I, Ibanez de Caceres I, Hoffman AM, Potapova A, Dulaimi E, Al-Saleem T, Hudes GR, Ochs MF, Cairns P. 2010. Global reactivation of epigenetically silenced genes in prostate cancer. Cancer Prev Res (Phila) 3: 1084-1092.
44. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, Cui H, Gabo K, Rongione M, Webster M, et al. 2009. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 41: 178-186.
45. Issa JP. 2004. CpG island methylator phenotype in cancer. Nat Rev Cancer 4: 988-993.
46. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. 2011. Global cancer statistics. CA Cancer J Clin 61: 69-90.
47. Jensen TJ, Novak P, Eblin KE, Gandolfi AJ, Futscher BW. 2008. Epigenetic remodeling during arsenical-induced malignant transformation. Carcinogenesis 29: 1500-1508.
48. Jones PA. 2002. DNA methylation and cancer. Oncogene 21: 5358-5360.
49. Ju YS, Lee WC, Shin JY, Lee S, Bleazard T, Won JK, Kim YT, Kim JI, Kang JH, Seo JS. 2012. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res 22: 436-445.
50. Kaur S, Leszczynska K, Abraham S, Scarcia M, Hiltbrunner S, Marshall CJ, Mavria G, Bicknell R, Heath VL. 2011. RhoJ/TCL regulates endothelial motility and tube formation and modulates actomyosin contractility and focal adhesion numbers. Arterioscler Thromb Vasc Biol 31: 657-664.
51. Kerr KM, Galler JS, Hagen JA, Laird PW, Laird-Offringa IA. 2007. The role of DNA methylation in the development and progression of lung adenocarcinoma. Dis Markers 23: 5-30.
52. Kikuchi S, Yamada D, Fukami T, Masuda M, Sakurai-Yageta M, Williams YN, Maruyama T, Asamura H, Matsuno Y, Onizuka M, et al. 2005. Promoter methylation of DAL-1/4.1B predicts poor prognosis in non-small cell lung cancer. Clin Cancer Res 11: 2954-2961.
53. Kim H, Lapointe J, Kaygusuz G, Ong DE, Li C, van de Rijn M, Brooks JD, Pollack JR. 2005. The retinoic acid synthesis gene ALDH1a2 is a candidate tumor suppressor in prostate cancer. Cancer Res 65: 8118-8124.
54. Kobayashi K, Nishioka M, Kohno T, Nakamoto M, Maeshima A, Aoyagi K, Sasaki H, Takenoshita S, Sugimura H, Yokota J. 2004. Identification of genes whose expression is upregulated in lung adenocarcinoma cells in comparison with type II alveolar cells and bronchiolar epithelial cells in vivo. Oncogene 23: 3089-3096.
55. Kohda M, Hoshiya H, Katoh M, Tanaka I, Masuda R, Takemura T, Fujiwara M, Oshimura M. 2001. Frequent loss of imprinting of IGF2 and MEST in lung adenocarcinoma. Mol Carcinog 31: 184-191.
56. Kubo T, Yamamoto H, Ichimura K, Jida M, Hayashi T, Otani H, Tsukuda K, Sano Y, Kiura K, Toyooka S. 2009. DNA methylation in small lung adenocarcinoma with bronchioloalveolar carcinoma components. Lung Cancer 65: 328-332.
57. Kupershmidt I, Su QJ, Grewal A, Sundaresh S, Halperin I, Flynn J, Shekar M, Wang H, Park J, Cui W, et al. 2010. Ontology-based meta-analysis of global collections of high-throughput public data. PLoS ONE 5: e13066. doi: 10.1371/journal.pone.0013066.
58. Landi MT, Dracheva T, Rotunno M, Figueroa JD, Liu H, Dasgupta A, Mann FE, Fukuoka J, Hames M, Bergen AW, et al. 2008. Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS One 3: e1651. doi: 10.1371/journal.pone.0001651.
59. Larsen JE, Pavey SJ, Passmore LH, Bowman RV, Hayward NK, Fong KM. 2007. Gene expression signature predicts recurrence in lung adenocarcinoma. Clin Cancer Res 13: 2946-2954.
60. Leandro-Garcia LJ, Leskela S, Landa I, Montero-Conde C, Lopez-Jimenez E, Leton R, Cascon A, Robledo M, Rodriguez-Antona C. 2010. Tumoral and tissue-specific expression of the major human b-tubulin isotypes. Cytoskeleton (Hoboken) 67: 214-223.
61. Leek JT, Scharpf RB, Bravo HC, Simcha D, Langmead B, Johnson WE, Geman D, Baggerly K, Irizarry RA. 2010. Tackling the widespread and critical impact of batch effects in high-throughput data. Nat Rev Genet 11: 733-739.
62. Lehtonen ST, Svensk AM, Soini Y, Paakko P, Hirvikoski P, Kang SW, Saily M, Kinnula VL. 2004. Peroxiredoxins, a novel protein family in lung cancer. Int J Cancer 111: 514-521.
63. Lemjabbar-Alaoui H, Dasari V, Sidhu SS, Mengistab A, Finkbeiner W, Gallup M, Basbaum C. 2006. Wnt and Hedgehog are critical mediators of cigarette smoke-induced lung cancer. PLoS ONE 1: e93. doi: 10.1371/journal.pone.0000093.
64. Leppanen VM, Bespalov MM, Runeberg-Roos P, Puurand U, Merits A, Saarma M, Goldman A. 2004. The structure of GFRα1 domain 3 reveals new insights into GDNF binding and RET activation. EMBO J 23: 1452-1462.
65. Li Y, Dong X, Yin Y, Su Y, Xu Q, Zhang Y, Pang X, Chen W. 2005. BJ-TSA-9, a novel human tumor-specific gene, has potential as a biomarker of lung cancer. Neoplasia 7: 1073-1080.
66. Li L, Lee KM, Han W, Choi JY, Lee JY, Kang GH, Park SK, Noh DY, Yoo KY, Kang D. 2010. Estrogen and progesterone receptor status affect genome-wide DNA methylation profile in breast cancer. Hum Mol Genet 19: 4273-4277.
67. Li N, Grivennikov SI, Karin M. 2011. The unholy trinity: Inflammation, cytokines, and STAT3 shape the cancer microenvironment. Cancer Cell 19: 429-431.
68. Lind GE, Ahlquist T, Lothe RA. 2007. DNA hypermethylation of MAL: A promising diagnostic biomarker for colorectal tumors. Gastroenterology 132: 1631-1632.
69. Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, Jarosz M, Curran JA, Balasubramanian S, Bloom T, Brennan KW, et al. 2012. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 18: 382-384.
70. Liu L, Liao GQ, He P, Zhu H, Liu PH, Qu YM, Song XM, Xu QW, Gao Q, Zhang Y, et al. 2008. Detection of circulating cancer cells in lung cancer patients with a panel of marker genes. Biochem Biophys Res Commun 372: 756-760.
71. Lopez-Serra P, Esteller M. 2012. DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer. Oncogene 31: 1609-1622.
72. Lu TP, Tsai MH, Lee JM, Hsu CP, Chen PC, Lin CW, Shih JY, Yang PC, Hsiao CK, Lai LC, et al. 2010. Identification of a novel biomarker, SEMA5A, for non-small cell lung carcinoma in nonsmoking women. Cancer Epidemiol Biomarkers Prev 19: 2590-2597.
73. Marsit CJ, Houseman EA, Christensen BC, Eddy K, Bueno R, Sugarbaker DJ, Nelson HH, Karagas MR, Kelsey KT. 2006. Examination of a CpG island methylator phenotype and implications of methylation profiles in solid tumors. Cancer Res 66: 10621-10629.
74. Maunakea AK, Nagarajan RP, Bilenky M, Ballinger TJ, D'Souza C, Fouse SD, Johnson BE, Hong C, Nielsen C, Zhao Y, et al. 2010. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature 466: 253-257.
75. Mazieres J, He B, You L, Xu Z, Jablons DM. 2005. Wnt signaling in lung cancer. Cancer Lett 222: 1-10.
76. Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A, Politi LS, Gentner B, Brown JL, Naldini L, et al. 2011. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 19: 512-526.
77. Mura M, Swain RK, Zhuang X, Vorschmitt H, Reynolds G, Durant S, Beesley JF, Herbert JM, Sheldon H, Andre M, et al. 2012. Identification and angiogenic role of the novel tumor endothelial marker CLEC14A. Oncogene 31: 293-305.
78. Nguyen DX, Chiang AC, Zhang XH, Kim JY, Kris MG, Ladanyi M, Gerald WL, Massague J. 2009. WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 138: 51-62.
79. Nishihara H, Maeda M, Oda A, Tsuda M, Sawa H, Nagashima K, Tanaka S. 2002. DOCK2 associates with CrkL and regulates Rac1 in human leukemia cell lines. Blood 100: 3968-3974.
80. Niwa Y, Kanda H, Shikauchi Y, Saiura A, Matsubara K, Kitagawa T, Yamamoto J, Kubo T, Yoshikawa H. 2005. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene 24: 6406-6417.
81. Noordhuis MG, Fehrmann RS, Wisman GB, Nijhuis ER, van Zanden JJ, Moerland PD, Ver Loren van Themaat E, Volders HH, Kok M, ten Hoor KA, et al. 2011. Involvement of the TGF-β and β-catenin pathways in pelvic lymph node metastasis in early-stage cervical cancer. Clin Cancer Res 17: 1317-1330.
82. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, et al. 2010. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17: 510-522.
83. Ogino S, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. 2006. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: Possible associations with male sex and KRAS mutations. J Mol Diagn 8: 582-588.
84. Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, Cope L, Mohammad HP, Chen W, Daniel VC, Yu W, et al. 2007. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 39: 237-242.
85. Oka R, Sasagawa T, Ninomiya I, Miwa K, Tanii H, Saijoh K. 2001. Reduction in the local expression of complement component 6 (C6) and 7 (C7) mRNAs in oesophageal carcinoma. Eur J Cancer 37: 1158-1165.
86. Osada H, Tatematsu Y, Yatabe Y, Nakagawa T, Konishi H, Harano T, Tezel E, Takada M, Takahashi T. 2002. Frequent and histological type-specific inactivation of 14-3-3s in human lung cancers. Oncogene 21: 2418-2424.
87. Oster B, Thorsen K, Lamy P, Wojdacz TK, Hansen LL, Birkenkamp-Demtroder K, Sorensen KD, Laurberg S, Orntoft TF, Andersen CL. 2011. Identification and validation of highly frequent CpG island hypermethylation in colorectal adenomas and carcinomas. Int J Cancer 129: 2855-2866.
88. Pao W, Girard N. 2011. New driver mutations in non-small-cell lung cancer. Lancet Oncol 12: 175-180.
89. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, et al. 2004. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci 101: 13306-13311.
90. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H. 2005a. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a secondmutation in the EGFR kinase domain. PLoS Med 2: e73. doi: 10.1371/journal.pmed.0020073.
91. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG, Varmus HE. 2005b. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2: e17. doi: 10.1371/journal.pmed.0020017.
92. Park K, Chung YJ, So H, Kim K, Park J, Oh M, Jo M, Choi K, Lee EJ, Choi YL, et al. 2011. AGR2, a mucinous ovarian cancer marker, promotes cell proliferation and migration. Exp Mol Med 43: 91-100.
93. Pedersen KS, Bamlet WR, Oberg AL, de Andrade M, Matsumoto ME, Tang H, Thibodeau SN, Petersen GM, Wang L. 2011. Leukocyte DNA methylation signature differentiates pancreatic cancer patients from healthy controls. PLoS ONE 6: e18223. doi: 10.1371/journal.pone.0018223.
94. Piepoli A, Cotugno R, Merla G, Gentile A, Augello B, Quitadamo M, Merla A, Panza A, Carella M, Maglietta R, et al. 2009. Promoter methylation correlates with reduced NDRG2 expression in advanced colon tumour. BMC Med Genomics 2: 11. doi: 10.1186/1755-8794-2-11.
95. Pizzi M, Fassan M, Balistreri M, Galligioni A, Rea F, Rugge M. 2012. Anterior gradient 2 overexpression in lung adenocarcinoma. Appl Immunohistochem Mol Morphol 20: 31-36.
96. 6-methylguanine-DNA methyltransferase gene: More common in lung adenocarcinomas from never-smokers than smokers and associated with tumor progression. Cancer Res 63: 4842-4848.
97. Pyle-Chenault RA, Stolk JA, Molesh DA, Boyle-Harlan D, McNeill PD, Repasky EA, Jiang Z, Fanger GR, Xu J. 2005. VSGP/F-spondin: A new ovarian cancer marker. Tumour Biol 26: 245-257.
98. R Development Core Team. 2011. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/.
99. Ramachandran V, Arumugam T, Wang H, Logsdon CD. 2008. Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival. Cancer Res 68: 7811-7818.
100. Rauch T, Wang Z, Zhang X, Zhong X, Wu X, Lau SK, Kernstine KH, Riggs AD, Pfeifer GP. 2007. Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay. Proc Natl Acad Sci 104: 5527-5532.
101. Remmelink M, Mijatovic T, Gustin A, Mathieu A, Rombaut K, Kiss R, Salmon I, Decaestecker C. 2005. Identification by means of cDNA microarray analyses of gene expression modifications in squamous non-small cell lung cancers as compared to normal bronchial epithelial tissue. Int J Oncol 26: 247-258.
102. Risch A, Plass C. 2008. Lung cancer epigenetics and genetics. Int J Cancer 123: 1-7.
103. Rodenhiser DI, Andrews J, Kennette W, Sadikovic B, Mendlowitz A, Tuck AB, Chambers AF. 2008. Epigenetic mapping and functional analysis in a breast cancer metastasis model using whole-genome promoter tiling microarrays. Breast Cancer Res 10: R62. doi: 10.1186/bcr2121.
104. Rodriguez-Paredes M, Esteller M. 2011. Cancer epigenetics reaches mainstream oncology. Nat Med 17: 330-339.
105. Rohan S, Tu JJ, Kao J, Mukherjee P, Campagne F, Zhou XK, Hyjek E, Alonso MA, Chen YT. 2006. Gene expression profiling separates chromophobe renal cell carcinoma from oncocytoma and identifies vesicular transport and cell junction proteins as differentially expressed genes. Clin Cancer Res 12: 6937-6945.
106. Rui X, Tsao J, Scheys JO, Hammer GD, Schimmer BP. 2008. Contributions of specificity protein-1 and steroidogenic factor 1 to Adcy4 expression in Y1 mouse adrenal cells. Endocrinology 149: 3668-3678.
107. Sakakura C, Hasegawa K, Miyagawa K, Nakashima S, Yoshikawa T, Kin S, Nakase Y, Yazumi S, Yamagishi H, Okanoue T, et al. 2005. Possible involvement of RUNX3 silencing in the peritoneal metastases of gastric cancers. Clin Cancer Res 11: 6479-6488.
108. Sakhinia E, Farahangpour M, Tholouli E, Liu Yin JA, Hoyland JA, Byers RJ. 2006. Comparison of gene-expression profiles in parallel bone marrow and peripheral blood samples in acute myeloid leukaemia by real-time polymerase chain reaction. J Clin Pathol 59: 1059-1065.
109. Sakthianandeswaren A, Christie M, D'Andreti C, Tsui C, Jorissen RN, Li S, Fleming NI, Gibbs P, Lipton L, Malaterre J, et al. 2011. PHLDA1 expression marks the putative epithelial stem cells and contributes to intestinal tumorigenesis. Cancer Res 71: 3709-3719.
110. - squamous cell carcinoma cell lines are consistent with divergent mechanisms of carcinogenesis. Epigenetics 6: 777-787.
111. Satelli A, Rao PS, Thirumala S, Rao US. 2011. Galectin-4 functions as a tumor suppressor of human colorectal cancer. Int J Cancer 129: 799-809.
112. Sathyanarayana UG, Toyooka S, Padar A, Takahashi T, Brambilla E, Minna JD, Gazdar AF. 2003. Epigenetic inactivation of laminin-5-encoding genes in lung cancers. Clin Cancer Res 9: 2665-2672.
113. Sato M, Mori Y, Sakurada A, Fujimura S, Horii A. 1998. The H-cadherin (CDH13) gene is inactivated in human lung cancer. Hum Genet 103: 96-101.
114. Sato N, Fukushima N, Maitra A, Matsubayashi H, Yeo CJ, Cameron JL, Hruban RH, Goggins M. 2003. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 63: 3735-3742.
115. Schimanski S, Wild PJ, Treeck O, Horn F, Sigruener A, Rudolph C, Blaszyk H, Klinkhammer-Schalke M, Ortmann O, Hartmann A, et al. 2010. Expression of the lipid transporters ABCA3 and ABCA1 is diminished in human breast cancer tissue. Horm Metab Res 42: 102-109.
116. Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J, Eden E, Yakhini Z, Ben-Shushan E, Reubinoff BE, et al. 2007. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 39: 232-236.
117. Selamat SA, Galler JS, Joshi AD, Fyfe MN, Campan M, Siegmund KD, Kerr KM, Laird-Offringa IA. 2011. DNA methylation changes in atypical adenomatous hyperplasia, adenocarcinoma in situ, and lung adenocarcinoma. PLoS ONE 6: e21443. doi: 10.1371/journal.pone.0021443.
118. Shen L, Toyota M, Kondo Y, Lin E, Zhang L, Guo Y, Hernandez NS, Chen X, Ahmed S, Konishi K, et al. 2007. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci 104: 18654-18659.
119. Shiba-Ishii A, Kano J, Morishita Y, Sato Y, Minami Y, Noguchi M. 2011. High expression of stratifin is a universal abnormality during the course of malignant progression of early-stage lung adenocarcinoma. Int J Cancer 129: 2445-2453.
120. Shimizu H, Horii A, Sunamura M, Motoi F, Egawa S, Unno M, Fukushige S. 2011. Identification of epigenetically silenced genes in human pancreatic cancer by a novel method "microarray coupled with methyl-CpG targeted transcriptional activation" (MeTA-array). Biochem Biophys Res Commun 411: 162-167.
121. Shiraishi M, Sekiguchi A, Oates AJ, Terry MJ, Miyamoto Y. 2002. HOX gene clusters are hotspots of de novo methylation in CpG islands of human lung adenocarcinomas. Oncogene 21: 3659-3662.
122. Shulenin S, Nogee LM, Annilo T, Wert SE, Whitsett JA, Dean M. 2004. ABCA3 gene mutations in newborns with fatal surfactant deficiency. N Engl J Med 350: 1296-1303.
123. Storey JD, Tibshirani R. 2003. Statistical significance for genomewide studies. Proc Natl Acad Sci 100: 9440-9445.
124. Sun S, Schiller JH, Gazdar AF. 2007. Lung cancer in never smokers - a different disease. Nat Rev Cancer 7: 778-790.
125. Sunaga N, Imai H, Shimizu K, Shames DS, Kakegawa S, Girard L, Sato M, Kaira K, Ishizuka T, Gazdar AF, et al. 2012. Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer. Int J Cancer 130: 1733-1744.
126. Suzuki M, Shigematsu H, Iizasa T, Hiroshima K, Nakatani Y, Minna JD, Gazdar AF, Fujisawa T. 2006. Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer. Cancer 106: 2200-2207.
127. Suzuki-Ishigaki S, Numayama-Tsuruta K, Kuramasu A, Sakurai E, Makabe Y, Shimura S, Shirato K, Igarashi K, Watanabe T, Ohtsu H. 2000. The mouse L-histidine decarboxylase gene: Structure and transcriptional regulation by CpG methylation in the promoter region. Nucleic Acids Res 28: 2627-2633.
128. Tanaka S, Pero SC, Taguchi K, Shimada M, Mori M, Krag DN, Arii S. 2006. Specific peptide ligand for Grb7 signal transduction protein and pancreatic cancer metastasis. J Natl Cancer Inst 98: 491-498.
129. Tao R, Li J, Xin J, Wu J, Guo J, Zhang L, Jiang L, Zhang W, Yang Z, Li L. 2011. Methylation profile of single hepatocytes derived from hepatitis B virus-related hepatocellular carcinoma. PLoS ONE 6: e19862. doi: 10.1371/journal.pone.0019862.
130. Teodoridis JM, Hardie C, Brown R. 2008. CpG island methylator phenotype (CIMP) in cancer: Causes and implications. Cancer Lett 268: 177-186.
131. Tessema M, Belinsky SA. 2008. Mining the epigenome for methylated genes in lung cancer. Proc Am Thorac Soc 5: 806-810.
132. Toh CK, Gao F, Lim WT, Leong SS, Fong KW, Yap SP, Hsu AA, Eng P, Koong HN, Thirugnanam A, et al. 2006. Never-smokers with lung cancer: Epidemiologic evidence of a distinct disease entity. J Clin Oncol 24: 2245-2251.
133. Tommasi S, Kim SI, Zhong X, Wu X, Pfeifer GP, Besaratinia A. 2010. Investigating the epigenetic effects of a prototype smoke-derived carcinogen in human cells. PLoS ONE 5: e10594. doi: 10.1371/journal.pone.0010594.
134. Toyooka S, Maruyama R, Toyooka KO, McLerran D, Feng Z, Fukuyama Y, Virmani AK, Zochbauer-Muller S, Tsukuda K, Sugio K, et al. 2003. Smoke exposure, histologic type and geography-related differences in the methylation profiles ofnon-small cell lung cancer. Int J Cancer 103: 153-160.
135. Toyooka S, Tokumo M, Shigematsu H, Matsuo K, Asano H, Tomii K, Ichihara S, Suzuki M, Aoe M, Date H, et al. 2006. Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers. Cancer Res 66: 1371-1375.
136. Toyoshima Y, Karas M, Yakar S, Dupont J, Lee H, LeRoith D. 2004. TDAG51 mediates the effects of insulin-like growth factor I (IGF-I) on cell survival. J Biol Chem 279: 25898-25904.
137. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. 1999. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci 96: 8681-8686.
138. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, et al. 2011. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6: 244-285.
139. Tripodi D, Quemener S, Renaudin K, Ferron C, Malard O, Guisle-Marsollier I, Sebille-Rivain V, Verger C, Geraut C, Gratas-Rabbia-Re C. 2009. Gene expression profiling in sinonasal adenocarcinoma. BMC Med Genomics 2: 65. doi: 10.1186/1755-8794-2-65.
140. Tsou JA, Shen LY, Siegmund KD, Long TI, Laird PW, Seneviratne CK, Koss MN, Pass HI, Hagen JA, Laird-Offringa IA. 2005. Distinct DNA methylation profiles in malignant mesothelioma, lung adenocarcinoma, and non-tumor lung. Lung Cancer 47: 193-204.
141. Tsou JA, Galler JS, Siegmund KD, Laird PW, Turla S, Cozen W, Hagen JA, Koss MN, Laird-Offringa IA. 2007. Identification of a panel of sensitive and specific DNA methylation markers for lung adenocarcinoma. Mol Cancer 6: 70.
142. Usadel H, Brabender J, Danenberg KD, Jeronimo C, Harden S, Engles J, Danenberg PV, Yang S, Sidransky D. 2002. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res 62: 371-375.
143. Vaissiere T, Hung RJ, Zaridze D, Moukeria A, Cuenin C, Fasolo V, Ferro G, Paliwal A, Hainaut P, Brennan P, et al. 2009. Quantitative analysis of DNA
144. van Vlodrop IJ, Niessen HE, Derks S, Baldewijns M, Van Criekinge W, Herman JG, van Engeland M. 2011. Analysis of promoter CpG island hypermethylation in cancer: Location, location, location! Clin Cancer Res 17: 4225-4231.
145. Vanderlaag KE, Hudak S, Bald L, Fayadat-Dilman L, Sathe M, Grein J, Janatpour MJ. 2010. Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-a and survivin. Breast Cancer Res 12: R32. doi: 10.1186/bcr2586.
146. Vitale L, Frabetti F, Huntsman SA, Canaider S, Casadei R, Lenzi L, Facchin F, Carinci P, Zannotti M, Coppola D, et al. 2007. Sequence, "subtle"alternative splicing and expression of the CYYR1 (cysteine/tyrosine-rich 1) mRNA in human neuroendocrine tumors. BMC Cancer 7: 66. doi: 10.1186/1471-2407-7-66.
147. Walker BA, Wardell CP, Chiecchio L, Smith EM, Boyd KD, Neri A, Davies FE, Ross FM, Morgan GJ. 2011. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood 117: 553-562.
148. Wang S, El-Deiry WS. 2003. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22: 8628-8633.
149. Wang KK, Liu N, Radulovich N, Wigle DA, Johnston MR, Shepherd FA, Minden MD, Tsao MS. 2002. Novel candidate tumor marker genes for lung adenocarcinoma. Oncogene 21: 7598-7604.
150. Wang L, Aakre JA, Jiang R, Marks RS, Wu Y, Chen J, Thibodeau SN, Pankratz VS, Yang P. 2010. Methylation markers for small cell lung cancer in peripheral blood leukocyte DNA. J Thorac Oncol 5: 778-785.
151. Watanabe M, Takemasa I, Kaneko N, Yokoyama Y, Matsuo E, Iwasa S, Mori M, Matsuura N, Monden M, Nishimura O. 2011. Clinical significance of circulating galectins as colorectal cancer markers. Oncol Rep 25: 1217-1226.
152. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D, et al. 2006. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38: 787-793.
153. Wikman H, Kettunen E, Seppanen JK, Karjalainen A, Hollmen J, Anttila S, Knuutila S. 2002. Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array. Oncogene 21: 5804-5813.
154. Wrage M, Ruosaari S, Eijk PP, Kaifi JT, Hollmen J, Yekebas EF, Izbicki JR, Brakenhoff RH, Streichert T, Riethdorf S, et al. 2009. Genomic profiles associated with early micrometastasis in lung cancer: Relevance of 4q deletion. Clin Cancer Res 15: 1566-1574.
155. Yagi K, Akagi K, Hayashi H, Nagae G, Tsuji S, Isagawa T, Midorikawa Y, Nishimura Y, Sakamoto H, Seto Y, et al. 2010. Three DNA methylation epigenotypes in human colorectal cancer. Clin Cancer Res 16: 21-33.
156. Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE, Harris CC, Herman JG. 2001. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 28: 29-35.
157. Yue W, Dacic S, Sun Q, Landreneau R, Guo M, Zhou W, Siegfried JM, Yu J, Zhang L. 2007. Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter hypermethylation. Clin Cancer Res 13: 4336-4344.
158. Zhang W, Glockner SC, Guo M, Machida EO, Wang DH, Easwaran H, Van Neste L, Herman JG, Schuebel KE, Watkins DN, et al. 2008. Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res 68: 2764-2772.